GSK, Merck partner up to develop cancer immunotherapy in $4.2 billion deal

This global strategic alliance will see the two drugmakers jointly develop and commercialize bintrafusp alfa, an investigational bifunctional fusion protein immunotherapy that is currently in clinical development for multiple difficult-to-treat cancers
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news